Extraction Archives - Green Market Report

StaffStaffAugust 18, 2020
shutterstock_1789366847-1280x842.jpg

4min9950

Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s License, Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) announced that it is the first organization to exercise its cGMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction.

Mydecine™ has the full range of capabilities to extract fungi’s natural psychedelic compounds, such as psilocybin and psilocin from certain species of fruiting body mushrooms all the way through to distribution. Mydecine™ also has the ability to conduct the most advanced techniques to produce purified pharmaceutical-grade extract, then legally export its finished byproducts to its various research partners throughout the world, including but not limited to the Imperial College of London and Johns Hopkins University.

The Company is also capable of supporting commercial research institutions with product donations, including charitable contributions to provide its purified extracts and formulations to end-of-life distressed patients. The announcement comes on the heels of a recent landmark decision by Health Canada to permit four terminally ill patients to consume psilocybin mushrooms to ease their distress. This historic decision establishes a precedent that will pave the way for a wider adoption of psilocybin-based therapies.

“Mydecine’s breakthrough to legally supply naturally-sourced psilocybin within our spore-to-sale™ process will be a major advancement for mental therapeutics, due to the fact that these unique psychedelic compounds are both safe and effective for afflictions, such as depression, anxiety, and PTSD,” quoted Damon Michaels, COO and Co-Founder of Mydecine™.

There is still debate as to which is more successful in psychedelic-based treatments between naturally derived psilocybin or the use of a synthetic form. Given Mydecine’s full legal ability to access both types of active compounds, the Company is poised to internally answer that question as well as aid various qualified groups also conducting this type of research. In theory, there are a plethora of added benefits in regard to the entourage effect of naturally-sourced psilocybin versus the synthetic route. Additionally, Mydecine™ is developing a number of unique API’s from their naturally-sourced cGMP psychedelic extracts. Mydecine™ will also be conducting R&D to produce novel proprietary formulations by synergizing psychedelic fungi compounds with other various API’s; Mydecine™ will then attach their formulations to their exclusive delivery mechanisms. Mydecine™ plans to utilize these psychedelic medicinal formulations in various clinical environments around the world in aspiration to better the lives of many.

The Company notes that although several international companies and research institutions are permitted to utilize synthesized psilocybin, the process is extremely challenging and cost prohibitive with a single gram having the price tag of thousands of dollars. Being able to legally extract psilocybin from its natural source, Mydecine™ will hope to reduce these significant costs and improve the scalability of world-class research initiatives and novel therapies.

CEO and Director of Mydecine™, Joshua Bartch stated, “We are extremely grateful to have the ability to provide cGMP psychedelic API’s to qualified organizations, research partners, nonprofits, and clinical groups throughout the globe. We believe the reason current psilocybin-based research initiatives come with a very high cost using inefficiently produced synthetic psilocybin is simply due to a lack of capabilities and legal restraints. Mydecine’s legal capabilities through the dealer’s license will incorporate our range of abilities, which will be valuable for naturally-sourced medicine paired with new-age technology. We believe our achievement is the first-of-its-kind.”


AxisWireAxisWireAugust 18, 2020
logo_mydecine-2.png

9min11220

Being Facilitated Under a Schedule 1 Health Canada Dealer’s License

DENVER, Colorado, USA, August 18, 2020 /AxisWire/ Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine™” or the “Company”) is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom extraction.

Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealer’s License, Mydecine™ has the full range of capabilities to extract fungi’s natural psychedelic compounds, such as psilocybin and psilocin from certain species of fruiting body mushrooms all the way through to distribution. Mydecine™ also has the ability to conduct the most advanced techniques to produce purified pharmaceutical-grade extract, then legally export its finished byproducts to its various research partners throughout the world, including but not limited to the Imperial College of London and Johns Hopkins University.

The Company is also capable of supporting commercial research institutions with product donations, including charitable contributions to provide its purified extracts and formulations to end-of-life distressed patients. The announcement comes on the heels of a recent landmark decision by Health Canada to permit four terminally ill patients to consume psilocybin mushrooms to ease their distress. This historic decision establishes a precedent that will pave the way for a wider adoption of psilocybin-based therapies.

“Mydecine’s breakthrough to legally supply naturally-sourced psilocybin within our spore-to-sale™ process will be a major advancement for mental therapeutics, due to the fact that these unique psychedelic compounds are both safe and effective for afflictions, such as depression, anxiety, and PTSD,” quoted Damon Michaels, COO and Co-Founder of Mydecine™.

There is still debate as to which is more successful in psychedelic-based treatments between naturally derived psilocybin or the use of a synthetic form. Given Mydecine’s full legal ability to access both types of active compounds, the Company is poised to internally answer that question as well as aid various qualified groups also conducting this type of research. In theory, there are a plethora of added benefits in regard to the entourage effect(₂) of naturally-sourced psilocybin versus the synthetic route. Additionally, Mydecine™ is developing a number of unique API’s(₃) from their naturally-sourced cGMP psychedelic extracts. Mydecine™ will also be conducting R&D to produce novel proprietary formulations by synergizing psychedelic fungi compounds with other various API’s; Mydecine™ will then attach their formulations to their exclusive delivery mechanisms. Mydecine™ plans to utilize these psychedelic medicinal formulations in various clinical environments around the world in aspiration to better the lives of many.

The Company notes that although several international companies and research institutions are permitted to utilize synthesized psilocybin, the process is extremely challenging and cost prohibitive(₄) with a single gram having the price tag of thousands of dollars. Being able to legally extract psilocybin from its natural source, Mydecine™ will hope to reduce these significant costs and improve the scalability of world-class research initiatives and novel therapies.

CEO and Director of Mydecine™, Joshua Bartch stated, “We are extremely grateful to have the ability to provide cGMP psychedelic API’s to qualified organizations, research partners, nonprofits, and clinical groups throughout the globe. We believe the reason current psilocybin-based research initiatives come with a very high cost using inefficiently produced synthetic psilocybin is simply due to a lack of capabilities and legal restraints. Mydecine’s legal capabilities through the dealer’s license will incorporate our range of abilities, which will be valuable for naturally-sourced medicine paired with new-age technology. We believe our achievement is the first-of-its-kind.”

1 Current Good Manufacturing Practices. GMP is a system for ensuring that products are consistently produced and controlled according to the best quality standards.

2The“entourage effect” is a proposed mechanism by which active compounds act synergistically to modulate the overall effects of multiple active compounds working together to produce a polypharmaceutical medicine.

3Active Pharmaceutical Ingredient/s are single or poly ingredients in pharmaceutical medicines that are biologically active.

4 Current synthesized psilocybin applied to recent psychedelic research sells for ~$7-10k USD per gram.

 

About Mydecine Innovations Group Inc.
Mydecine Innovations Group™is a publicly traded life sciences parent company with offices in Denver, CO and Vancouver, BC. Mydecine™ is dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine’s experienced cross functional teams have the dynamic capabilities to oversee all areas of medicine development, including synthesis, genetic research, import/export, delivery system design, clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof. This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company.Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including,without limitation, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. This news release does not constitute an offer of securities for sale in the United States. These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.


Julie AitchesonJulie AitchesonJune 11, 2020
Blinc2.png

6min6830

The summer of 2019 pales in comparison to the turmoil of pretty much every month of 2020 thus far, but was still notable for at least one high-profile public health crisis. August 2019 saw a noted rise in vaping-related illnesses. The vaping crisis prompted the Food and Drug Administration to initiate comprehensive laboratory testing and ongoing investigations of cases in order to regulate the use of vaping products.

Vape sales for key states hit a high of $160 million in August 2019 according to the new State of Legal Cannabis report by Arcview and BDSA. By September, those sales dropped to $126 million.  Once it was determined that illegal manufacturers were the root of the problem, branded vape sales started to slowly recover. Fourth-quarter 2019 sales still showed signs of decline, but in December sales picked up by 11%.

States and the vaping industry are still waiting on concrete federal guidelines, and in the meantime, many manufacturers of vaping hardware and associated products are downsizing or disbanding due to the one-two punch of the vape crisis and Covid-19. 

Blinc Remains Resilient

There is at least one hopeful story on the vape industry horizon, however, and that is the resilient growth and success of The Blinc Group. The Blinc Group’s business model is built on a tripartite foundation of innovation, quality, and safety, and it seems to be working. Where many companies suffered lethal blows from the vape crisis and Covid-19, The Blinc Group has maintained a focus on expansion and upgrading their facilities to improve safety standards. I recently had the opportunity to speak with Arnaud Dumas du Rauly, CEO of The Blinc Group. 

Arnaud Dumas du Rauly is also the ISO (International Organization for Standardization) Chairman of Standards on Vaping Products and the Chairman of the European Commission on Standards on Vaping Products. In other words, The Blinc Group is serious about safety. This focus led to slower initial growth and higher product pricing than the industry standard, but with earnings for 2020 already matching earnings for all of 2019, The Blinc Group is seeing a major return on its investment. 

During our interview, du Rauly spoke passionately about emissions, one of the industry’s primary safety issues. Because oils can undergo a change of state when they are vaporized, it is not possible to fully assess the potential toxicity of a product without testing emissions, typically using something called a “puffer machine”. This type of testing is not yet required in the U.S., but du Rauly is evangelical about its importance, not just for his company but industry-wide.

When the Covid-19 crisis hit and customers became more health-conscious in their buying behavior, The Blinc Group found itself in high demand with its start-to-finish supply chain control, a ten-year relationship with manufacturing facilities in China (which enabled them to keep their production on track as Covid-19 peaked there), and components that are ISO and GMP (Good Manufacturing Practice) compliant. It also allowed them to consolidate a position in the Canadian market, which is a highly regulated environment that few vaping product manufacturers in the U.S. are prepared to navigate. 

Arnaud Dumas du Rauly admits that research has not yet caught up with the cannabis industry in terms of product safety, but in his own words, “the DNA of the company is making sure that safe products get out there.” The Blinc Group’s current trajectory suggests that success is also part of their genetic makeup.

 


StaffStaffMay 13, 2020
shutterstock_660308902-1280x796.jpg

9min29140

Ever since recreational cannabis has stolen the stage, people tend to forget that cannabis is one of the oldest and most trusted medicines on the planet.

The medicinal properties within the plant are responsible for managing the symptoms associated in patients suffering from Epilepsy, Autism, Crohn’s Disease, Cancer, PTSD, and Chronic Pain to name just a few.

These brands have developed some of the best practices and formulations in the industry to treat a myriad of ailments with patents pending across the globe.

Our team decided to break down a list of the most respected medical brands and products within the cannabis industry globally.

Here they are:

 

1.) Charlotte’s Web:

More than just CBD: CBD plus naturally-occurring phytocannabinoids, terpenes, flavonoids and more in every CBD oil serving. The team from Charlotte’s Web uses limited, select ingredients to ensure you have the absolute best hemp extract possible. Their CBD oils include Charlotte’s Web premium hemp extract, carrier oil, and flavor. That’s it. Their products are U.S. Hemp Authority Certified. Charlotte’s Web CBD oils are whole-plant extracts that include a variety of of beneficial compounds, including phytocannabinoids, terpenes, flavonoids, and essential fatty acids.

 

2.) Aunt Zelda’s:

Aunt Zelda’s is a pioneering, data-driven developer of cannabis-based plant medicines. Our products are the result of years of research and development by founders, Mara Gordon and Stewart Smith, in consultation with knowledgeable physicians and world-renowned researchers.

Utilizing proven time-tested extraction processes improved with modern technology, Aunt Zelda’s offers medicines of precisely measured potency and purity that empower patients to dose to the milligram and unlock the therapeutic potential of cannabis.

If you prefer to obtain lab tested products created for specific ailments, Aunt Zelda’s will help you get there!

Aunt Zelda’s mission is to alleviate patient suffering through medical cannabis.  We help you, our patients, live fulfilling, healthy lives.

They provide unmatched expertise in the correct use of medical cannabis matched to disease-specific products with the highest purity in California.

Their goal is to create a positive and supportive community for medical cannabis users. They aspire to be your trusted source of cannabis resources and its safe, effective and responsible use

 

3.) HOPE Grows for Autism:

Formulation by: Zelira Therapeutics

HOPE is a Proprietary formulation specifically to address patient symptoms associated with Autism Spectrum Disorder.  The HOPE® Franchise has received support from organizations such as HOPE Grows for Autism, a leading autism advocacy group based in Pennsylvania. It has been the top performing product within the state and will soon be available for patients in Louisiana and throughout the US and Australia. 

In a company press release in December 2019, Zelira Therapeutics leadership said, “Our company will have the ability to distribute the HOPE® portfolio along with our additional products through licensing agreements with multi-state and international operators…”

HOPE 1 and HOPE 2 are part of a growing family of proprietary medical marijuana formulations. HOPE™ is created by extracting, isolating, and then re-assembling the medicinal compounds from the marijuana plant to achieve specific, targeted effects. HOPE™ was formulated with autism in mind and has quickly proved to be beneficial to other chronic conditions such as chronic pain, anxiety, neuropathy and others. HOPE™ has since become its manufacturer’s best-selling tincture.

 WHAT FORMS OF HOPE ARE AVAILABLE?

Available as a tincture, blended in 100% olive oil.

WHAT MAKES UP HOPE?

THC + CBD + Terpenes

Found in the trichomes of the plant, terpenes are plant oils with unique aromas and distinctive​ flavors (pine, citrus, mint) and are known to play​ a key role on the overall effects of each strain. ​ Terpenes also play a key role in differentiating​ the flavor and scent of marijuana. Some terpenes​ might promote relaxation, while others energy or​ focus.

 

4.) Ilera Holistic Healthcare:

ALAFIA — which means ‘inner peace’ in the Nigerian “Yoruba” language — is scientifically formulated, lab tested and pesticide free. Currently on the market are two formulated PURE CBD tinctures: Isolate CBD with 500mg and 1000mg  and Full Spectrum CBD with 500mg and 1000mg.  This product is Additional CBD products will be released at dispensaries in the state of Louisiana only.

“Our vision has always been patient access and affordability,” said Chanda Macias, chief executive officer of Ilera Holistic Healthcare. “It was imperative for us to bring high-quality products that support health and wellness.  Patients now have the ability to purchase ALAFIA over the counter without a prescription anywhere it is available.”  Dr. Chanda Macias said back in January 2020

5.) Haleigh’s Hope:

Extra strength has double the concentration than the regular strength, allowing the consumer to take less oil but still get the same desired therapeutic effect as the regular strength. Extra Strength products are recommended for people over 100 lbs.

This organically grown, whole plant extract contains a broad spectrum of naturally occurring plant based compounds that are clinically proven to provide a powerful combination of antioxidants and neuroprotectants. Haleigh’s Hope® was created from a proprietary genetic plant strain that was carefully bred and cultivated over seven years to achieve a precise combination of clinically proven, therapeutic plant compounds..

Haleigh’s Hope® grows, extracts, produces, packages and ships 100% of our product from our facilities in Colorado. Because we have exclusive control over our products from seed to sale, we ensure the highest levels of quality and consistency in the industry. Every batch of our product is lab tested for safety and quality.

Safflower is a cold pressed seed oil that is non-GMO and organic, and does not need to be shaken.

Exclusively grown and manufactured in Colorado, USA.


Debra BorchardtDebra BorchardtOctober 2, 2019
vaping.jpg

8min23890

Vape products, once considered the rising stars of the legal cannabis marketplace have struggled under the weight of the vaping crisis. Massachusetts banned all vape products for four months in order to err on the side of caution while the issue is investigated. Around the middle of August, vape product sales began dropping according to data from Headset, however, it seems the group may be slowly recovering. The following table was provided by Headset.

Sales in Nevada and Washington both began to pick back up, while California seems to have stabilized. Most consumers are learning that the issues with vapes stemmed from products purchased outside the regulated channels. 

A report from the CDC (Center for Disease Control) stated, “In addition, the report from Illinois and Wisconsin showed that nearly all THC-containing products reported were packaged, prefilled cartridges that were primarily acquired from informal sources such as friends, family members, illicit dealers, or off the street.”

It seems illicit market and unregulated vape producers were using thickening agents like Vitamin E with disastrous results. The industry, in general, has suggested that regulation will solve this issue and many are trying to convince the consumer that they can trust a regulated brand.

“The widely publicized public health issue relating to the use of liquid vapes is something that SLANG takes extremely seriously,” said SLANG Worldwide (OTC: SLGWF) CEO Peter Miller. “We encourage investigation and research into the causes of this issue and hope that our collective understanding of the results leads to more thorough and effective regulation of the industry.”

SLANG said it is not aware of any of its products being identified as a contributor to any of the recent illnesses associated with vaping technology. SLANG is not currently operating in Massachusetts and had postponed plans to enter that state. It doesn’t expect to be adversely impacted by Massachusetts’ temporary ban on vaping products.

1933 Industries (CSE: TGIF) (OTCQX: TGIFF) said, “All our branded THC and CBD vape products do not contain vitamin E acetate, vegetable glycerin, or propylene glycol. All our products are made with ingredients that are known to be safe for consumers. All packaging contains our product ingredients, which are also listed on our website. Each and every product is third-party lab tested, and the results can be tracked via a QR code.”

Testing Boom

Of course, in order to be sure testing is the best way to go and this crisis could present an opportunity for the lab group to capitalize. CannaSafe, California’s leading accredited cannabis testing laboratory said it will expand contaminant testing to Vitamin E additives, in response to ongoing concerns around consumer vaping safety. CannaSafe is the first laboratory to offer this service and will also provide testing for additional additives including medium-chain triglycerides, vegetable glycerin, and propylene glycol in the coming weeks.

“Trusted cannabis companies are taking it upon themselves to impose high-quality standards on consumer products, and we are ready to work with any business that wants to show customers that their products are free of toxic additives,” said Aaron Riley, CEO of CannaSafe. “We also urge brands and retailers to share test results with their customers as a gesture of good faith.”

Modern wellness company, dosist, is the first brand to voluntarily undergo Vitamin E testing with CannaSafe. Other brands that will utilize Cannasafe’s testing technology include Orchid Essentials, Select, Heavy Hitters, Stiiizy, King Pen, Lowell Herb Co., Pure Vape, Tikun, and Raw Garden. The Vitamin E test is available to brands and manufacturers across the state for an additional $225.

 


Debra BorchardtDebra BorchardtJuly 9, 2019
shutterstock_626109497-1280x853.jpg

7min30120

Cannabis and hemp extractor Radient Technologies Inc. (TSXV: RTI)(OTCQX: RDDTF) reported that the company lost C$18 million in its financial results for the fiscal year ending March 31, 2019.

The company only reported revenues of C$214,060 for the year and expenses of C$18,319,167. The cost for that revenue was C$131,249.

On a positive note, the company’s cash balance at the end of its fiscal year totaled C$31,752,852, representing an increase of $9,897,548 from March 31, 2018. This increase in cash is a result of equity placements the company closed on July 31, 2018, for aggregate proceeds of C$34,202,759.

The company said that the proceeds of these financings have been used to upgrade its main Edmonton extraction lines for dedicated cannabis and hemp extraction and purification and are being used for additional capacity in North America and Europe, as well as for general corporate and working capital purposes.

Lots Of Extraction Plans

The company noted that it has lots of extraction plans, but it seemed to be light on who is buying the finished product. Only Aurora Cannabis was mentioned as a customer and that agreement was signed in 2017.

“On February 4, 2019, Radient announced it had received its Standard Processing License from Health Canada under the new Cannabis Act. Radient’s preexisting Dealer’s License for its Research & Development Laboratory was also successfully transitioned under the new regulations.”

“Upon completion of the construction of the Canadian and German facilities, which is expected in the second half of calendar 2020, Radient will have an estimated combined total annual throughput capacity of more than 600,000 kg/year of cannabis, and more than 6 million kg/year of hemp.”

“In March 2019, the Company announced it had begun the commercial-scale extraction of cannabinoids from cannabis biomass using its patented, proprietary extraction and downstream processing platform at its Edmonton I facility. Post-fiscal 2019, in May 2019, Aurora Cannabis Inc. (TSX: ACB; NYSE: ACB) and Radient announced that Radient had successfully completed its first commercial delivery of cannabis derivatives to Aurora.”

Tobacco

While pushing ahead with the cannabis extraction, the company is also building up its low nicotine cigarette business.

“Radient filed a provisional patent application with the United States Patent and Trademark Office on June 5, 2018 for a proven method of significantly reducing nicotine levels in tobacco, while mostly maintaining the appearance, taste, and smell of the tobacco, via Radient’s proprietary continuous-flow extraction technology.”

“In March 2019, Radient announced the hire of two former British American Tobacco executives as senior executives of the Company. With their assistance, the company has developed and is executing a marketing strategy that targets tobacco companies, the FDA, advocacy groups and equipment manufacturers to ensure acceptance of the company’s technology in the industry as a viable industrial nicotine reduction technology.”


Debra BorchardtDebra BorchardtJune 26, 2019
canopy3-1280x854.jpg

3min15940

Canopy Growth Corporation (TSX:WEED, NYSE:CGC)  has acquired Saskatoon-based bio-product extractor KeyLeaf Life Sciences. Canopy Growth said it has been working closely with KeyLeaf – formerly known as POS Bio-Sciences – as a trusted partner building out extraction processes and technology for the past year as it refines its scale extraction model for Canadian and global markets.

“The KeyLeaf operations and team deliver instant scale at a pivotal stage in our growth, with brand new products coming to market later this year requiring sophisticated extraction capabilities at scale,” said Bruce Linton, Chairman & co-CEO, Canopy Growth Corporation. “This acquisition is the result of a year’s worth of work with a trusted partner, and part of our commitment to always staying a step ahead as leaders in a nascent industry, focused on the long-game one piece at a time.”

KeyLeaf has been working closely with Canopy Growth over the past year to retrofit its Saskatchewan facility to advance technology development and commercialization, in order to process hemp and cannabis biomass, and to conduct pre- and post-extraction processes.  It is anticipated the facility, which is currently in the Health Canada licensing process, will be able to process up to 5,000 kg of input materials daily when operational.

Canopy Growth said that it intends to leverage this facility, along with other owned and partner extraction options, to process its over 5,000 acres of Canadian CBD hemp production, over 160 acres of outdoor cannabis production, as well as any extraction materials outputted from its over 4 million square feet of greenhouse growing operations.  Then it’s off to Smiths Falls to produce the best possible, IP-protected products out there!

Back in November 2018, Canopy Growth assumed control of KeyLeaf for accounting purposes. This meant that KeyLeaf’s financial results were consolidated in the Canopy’s fiscal 2019 financial statements. Through the transaction, Canopy is buying a large-scale Canadian extraction facility as well as an extraction-related facility in the United States to support its U.S. CBD expansion.


StaffStaffJune 14, 2019
Dvr8IVXW0AI8vmj.jpg

4min21620

CannaCraft had a dilemma as one of California’s largest cannabis producers and distributors.

California is the largest market for cannabis in the U.S. Unfortunately, the flip side is that, with strict child-safety packaging requirements, it also produces the most amount of cannabis waste.

As a company that works towards cannabis advocacy, sustainability, charity work, compliance and safety, CannaCraft felt compelled to take a step back and reimagine its regulatory compliance tactics through the lens of environmental protection.

The company’s strict compliance with state packaging regulations meant that it was contributing significantly to California’s waste problem. Worse, it was afraid that as other states looked to California for guidance, the amount of waste generated would multiply, creating a tidal wave of ongoing waste generated across the country — a major environmental crisis.

Cannacraft first focused on a new packaging strategy for its vape product. The two million vape cartridges produced by CannaCraft annually were being packaged in plastic, child-resistant tubes to comply with cannabis packaging regulations in California. CannaCraft created a new step to the manufacturing process which allows it to simply seal the vape cartridges themselves, making them inherently child-resistant without adding excessive, single-use plastic.

“Public safety is naturally a top concern for CannaCraft, but the excessive plastic waste was also troubling,” says Tiffany Devitt, CannaCraft’s Chief Compliance Officer. “With each plastic tube standing 5.5” tall, 1 years’ worth of CannaCraft’s child-resistant tubes would reach over 900,000 feet if stacked. Or 30 times taller than Mount Everest. That’s a lot of waste that we’ll be eliminating.”

Innovation has been a driving force behind CannaCraft’s success, and, with over one hundred unique products, the company has amassed one of the largest product portfolios in California.

Dennis Hunter, CannaCraft’s co-founder said the company is in the process of reviewing its entire product lineup and production standards to improve sustainability and decrease the carbon footprint of the industry.

As a major producer of plastic waste, the cannabis industry must continue to innovate and demand regulations that take the environment into account. Consumers can also do their part. First, when feasible, support marijuana producers and retailers who are using recyclable or compostable packaging. Second, make an effort to recycle the parts of cannabis packaging that are recyclable, like paper, glass or cardboard. Third, in states that mandate exit packaging, such as California, aim to reuse your exit bag for all your cannabis purchases (just like bringing your own reusable bag to the supermarket!). Finally, advocate at the government level so that regulations are enacted that protect both people and our precious environment.

 


StaffStaffMay 3, 2019
Indose-Packaging-Image_Press-Kit-1024x683-1.jpg

4min20350

Indose, a groundbreaking precise dosage vaporizer that measures and displays exact dosage in real-time, down to the milligram, for a customized and controlled cannabis experience, announced today that it has closed a $3.5 million Series A round led by Casa Verde Capital.

Vaporizers are currently the fastest growing segment in cannabis, according to market research company ArcView. By next year, the vape segment of the legal marijuana industry in the United States is expected to more than triple to $3.9 billion. By 2021, vape sales are predicted to surge to a total of $5.2 billion — accounting for 25% of the entire industry.

Indose brings to market a proprietary metered vape pen technology that measures the precise dose — down to the milligram — of THC delivered with every draw. As a person inhales, their dosage is shown in real-time on an LED display that ranges from .05 MG to 4 MG, creating an individualized, controlled cannabis vaping experience.

The device is a drastic improvement over existing vaporizers on the market that provide either no control over dosage, or a one-size-fits-all approach using timers to deliver the same dose to everyone.

This $3.5 million raise will go towards expanding partnerships with cannabis oil manufacturers and brands across the country, increasing the size of the R&D team, filing for additional patents, and pursuing medical device certification.

“Dosage control is key to an effective and consistent cannabis experience, and there is no such thing as a universal dosage that is right for everyone,” said Indose co-founder and CEO Benzi Ronen.

Following three years of intensive research and development (and 15 filed patents) the Indose vaporizer features two proprietary sensors which take 10 measurements per second to calculate the precise milligrams of THC and CBD being inhaled by the user. This dosage is presented on the device in real time via an easy to read LED display. Whereas less sophisticated dosage-driven vapes deliver a “standard dose” between 2 and 3 MG, Indose allows users to micro-dose in .05 MG increments.

“We created Indose to address the critical gap we observed with first-generation vaporizers that guestimate dosage based on draw time or by moderating the temperature of the heating element. There is no universal dosage amount that is consistent to everyone regardless of their stature, experience or tolerance level. Dosage needs to be modified to each individual based on their receptors, body attributes and desired effects. With people using cannabis for therapeutic reasons in mind, we’ve developed a science-backed delivery system that’s both precise and personalized.”

Indose is democratizing this medical-grade device at an affordable price point. The vaporizer retails for less than $70, is recyclable, and comes paired with some of the world’s top cannabis oil brands — further customizing the experience. Indose is currently available in select pilot dispensaries in California and will announce a large-scale distribution partnership this summer.

“With decades of combined experience in product development and manufacturing, the Indose team was uniquely positioned to develop this innovative new technology,” said Karan Wadhera, Managing Partner of Casa Verde Capital. “We believe precise, self-regulated and responsible dosage will be the next frontier in vape delivery systems, and Indose is ahead of the curve with a device that brings medical precision to the mainstream.”

 


StaffStaffFebruary 12, 2019
Kurvana2.png

3min30790

The vape pen category has shown enormous growth in the cannabis industry, but not all vapes are created equal. Consumers are also beginning to show a preference in their purchasing habits when it comes to vapes as well. Kurvana has kept an eye on these trends and has managed to make a product to satisfy multiple consumers.

Cowen & Co.’s senior analyst Vivien Azer wrote that vape pens have grown their dollar share from 5.8% of the market in January 2016 to 14.7% in May 2018. Vapes have become the number two form factor in the cannabis industry trailing flower which commands a robust 52% of the market. However, flower sales have been losing ground to the vape pen sales.

Azer also determined that pricing varies for vape pens according to the market. For example, a vape pen in Washington state averages $26.31, while in Nevada that number jumps to $49.14. Consumers are also demanding to know more about their vape pens as the market gets flooded with products from dubious sources. Some companies buy their hardware from China from the same manufacturers that make e-cigarettes, but tobacco oil is thinner than cannabis oil, so additives are introduced in order to use the hardware.

Kurvana sources only the highest quality raw flower from organically grown cannabis, provided by trusted farmers well-known to the industry. Kurvana uses a proprietary 50-step process to purify the essential cannabinoids, tasty terpenes, and natural ingredients that contribute to the unique experience of vaping with full spectrum Kurvana oil. They never introduce extra terpenes or additives of any kind, because they distract from the plant’s original essence.

Consumers are also leaning more towards mood based vape pens versus strain based. Kurvana has captured both sides of this market. The ASCND pens offer 10 different strains that are clearly marked as to whether it is indica, sativa or a hybrid. Then the company’s website breaks it down even further into an easy to follow chart so that consumers can locate the symptom they want to address and find the pen to best address it.

The products are only available in California at this time, but with this is a high potency, attractive pen with a great taste that consumers will want to find.



About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 days

The Daily Hit: November 25, 2020

@GreenMarketRpt – 2 days

$PLNHF ⁦@Planet13lv⁩ Revenue Rises 36% To $22 Million, Turns A Profit

@GreenMarketRpt – 2 days

$VREOF ⁦@VireoHealth⁩ Revenue Rises 67%, Turns Profitable

Back to Top

You have Successfully Subscribed!